Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
09/28/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Letter Agreement, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D",
"Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity"
07/26/2023 8-K Quarterly results
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
05/23/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/04/2023 8-K Quarterly results
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity"
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates"
01/06/2023 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Updates to its Board of Directors"
10/27/2022 8-K Quarterly results
09/16/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Indenture, between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon, as trustee",
"Form of Capped Call Transaction Confirmation"
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes",
"Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes"
08/24/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
04/28/2022 8-K Quarterly results
Docs: "Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity"
04/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors CAMBRIDGE, Mass., - April 5, 2022 - Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced that Steven Paul, M.D. is retiring from the Board of Directors effective April 16, 2022. Dr. Paul has served as a member of the Alnylam Board of Directors since September 2010. He brought to the Board more than 25 years of management experience in the pharmaceutical industry and 35 years of scientific research experience during his time of service. He is widely recognized as a leader across many dimensions of medical research and drug development, including in the central nervous system , and late-stage clinical development. Dr. Paul is currently the Chief Executive Officer and Chair of the Board of Ka..."
04/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran"
03/17/2022 8-K Other Events  Interactive Data
02/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity"
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates"
01/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President"
12/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, between Alnylam Pharmaceuticals, Inc. and Dr. Yvonne L. Greenstreet",
"Employment Agreement, between Alnylam Pharmaceuticals, Inc. and Dr. Yvonne L. Greenstreet"
10/28/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D",
"Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity",
"Alnylam Announces Planned CEO Leadership Transition"
09/08/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Employment Agreement effective as of August 2, 2021 between the Company and John M. Maraganore, Ph.D",
"Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity"
05/21/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy